# Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

> **NCT02973789** · PHASE3 · COMPLETED · sponsor: **NovoCure GmbH** · enrollment: 291 (actual)

## Conditions studied

- Nonsmall Cell Lung Cancer
- NSCLC

## Interventions

- **DEVICE:** NovoTTF-200T
- **DRUG:** Immune checkpoint inhibitors or docetaxel

## Key facts

- **NCT ID:** NCT02973789
- **Lead sponsor:** NovoCure GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2024-09-24
- **Final completion:** 2024-10-09
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973789, "Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02973789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*